The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
A Randomized, Controlled Trial of Doxycycline and Rifampin for Patients with Alzheimer's Disease
Abstract
Objectives: To assess whether doxycycline and rifampin have a therapeutic role in patients with Alzheimer's disease (AD). Design: Randomized, triple‐blind, controlled trial. Setting: Three tertiary care and two community geriatric clinics in Canada. Participants: One hundred one patients with probable AD and mild to moderate dementia. Intervention: Oral daily doses of doxycycline 200 mg and rifampin 300 mg for 3 months. Measurements: The primary outcome was a change in Standardized Alzheimer's Disease Assessment Scale cognitive subscale (SADAScog) at 6 months. Secondary outcomes were changes in the SADAScog at 12 months and tests of dysfunctional behavior, depression, and functional status. Results: There was significantly less decline in the SADAScog score at 6 months in the antibiotic group than in the placebo group, (−2.75 points, 95% confidence interval (CI)=−5.28 to −0.22, P =.034). At 12 months, the difference between groups in the SADAScog was −4.31 points (95% CI=−9.17–0.56, P =.079). The antibiotic group showed significantly less dysfunctional behavior at 3 months. There was no significant difference in adverse events between groups ( P =.34). There were no differences in Chlamydia pneumoniae detection using polymerase chain reaction or antibodies (immunoglobulin (Ig)G or IgA) between groups. Conclusion: Therapy with doxycycline and rifampin may have a therapeutic role in patients with mild to moderate AD. The mechanism is unlikely to be due to their effect on C. pneumoniae . More research is needed to investigate these agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification and localization of Chlamydia pneumoniae in the Alzheimer's brain
Balin, B. J., Gérard, H. C., Arking, E. J., Appelt, D. M., Branigan, P. J., Abrams, J. T., Whittum-Hudson, J. A., & Hudson, A. P. (1998) · Medical Microbiology and Immunology · doi:10.1007/s004300050071 · Cited by 506
Cited by
Microbiota-Brain-Gut Axis and Neurodegenerative Diseases
Quigley, E. M. M. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0802-6 · Cited by 804
Microglia and neurodegeneration: The role of systemic inflammation
Cunningham, C. (2013) · Glia · doi:10.1002/glia.22350 · Cited by 769
Cirrito, J. R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25247 · Cited by 660
Enhancing mitochondrial proteostasis reduces amyloid-β proteotoxicity
Sorrentino, V., Romani, M., Mouchiroud, L., Beck, J. S., Zhang, H., D’Amico, D., Moullan, N., Potenza, F., Schmid, A. W., Rietsch, S., et al. (2017) · Nature · doi:10.1038/nature25143 · Cited by 630
Antibiotics, gut microbiota, and Alzheimer’s disease
Angelucci, F., Cechova, K., Amlerova, J., & Hort, J. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1494-4 · Cited by 454
Metadata
- Authors
- Loeb, M. B., Molloy, D. W., Smieja, M., Standish, T., Goldsmith, C. H., Mahony, J., Smith, S., Borrie, M., Decoteau, E., Davidson, W., Mcdougall, A., Gnarpe, J., O'donnell, M., & Chernesky, M.
- Venue
- Journal of the American Geriatrics Society
- Publisher
- Wiley
- Published
- 2004-02-12
- Volume
- 52
- Issue
- 3
- Pages
- 381-387
- ISSN
- 0002-8614 (ISSN-L)
- 1532-5415
- OpenAlex
- W1841389452
- Cited by
- 241
- References
- 1
- FWCI
- 3.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Randomized, Controlled Trial of Doxycycline and Rifampin for Patients with Alzheimer's Disease. https://app.cochat.ai/papers/10.1111/j.1532-5415.2004.52109.x
- The paper
- Loeb, M. B., Molloy, D. W., Smieja, M., Standish, T., Goldsmith, C. H., Mahony, J., Smith, S., Borrie, M., Decoteau, E., Davidson, W., Mcdougall, A., Gnarpe, J., O'donnell, M., & Chernesky, M. (2004). A Randomized, Controlled Trial of Doxycycline and Rifampin for Patients with Alzheimer's Disease. Journal of the American Geriatrics Society. https://doi.org/10.1111/j.1532-5415.2004.52109.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.